Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-15
2005-11-15
Dentz, Bernard (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S234500, C514S253040
Reexamination Certificate
active
06964971
ABSTRACT:
The invention relates generally to naphthyridine derivatives of the formulawherein one of U, X, Y and Z is nitrogen and the others are C—R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,6-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.
REFERENCES:
patent: 5217976 (1993-06-01), Ratcliffe et al.
patent: 5817669 (1998-10-01), Tomita et al.
patent: 6306856 (2001-10-01), Sawa
patent: 0227088 (1987-07-01), None
patent: 0366643 (1990-05-01), None
patent: 0516392 (1992-12-01), None
patent: 0856310 (1998-08-01), None
patent: 2256196 (1992-12-01), None
patent: 9805661 (1998-02-01), None
patent: 0008026 (2000-02-01), None
patent: 0016774 (2000-03-01), None
patent: 0071524 (2000-11-01), None
Patent Abstract of Japan, Pub. No.: 03058992, Pub. Date: Mar. 14, 1991, App. Date: Jul. 28, 1989, App. No.: 01/196,205, “New Isothiazolo-Naphthylidine, Isothiazoloquinoline Derivative and Salt Thereof”, Fukuoka Yoshikazu.
Patent Abstract of Japan, Pub. No.: 03223289, Pub. Date: Oct. 2, 1991, App. Date: Nov. 21, 1990, App. No.: 02319358, “Thienoquinoline Derivative, Thienonaphthyridine Derivative And Salt Thereof”, Nakada Katsuhisa.
Hermecz, I., Horvath, A., “Nitrogen Bridgehead Compounds. Part 83 [1], Synthesis and Ring Transformation of 6-Methyl-4-oxo-4H-pyrido[1,2-a]Pyrimidine-3-Acrylates”, J. Heterocyclic Chem., 29: 559-564 (1992).
Chu, D., Claiborne, A., “Practical Synthesis of Iminochlorothioformates: Application of Iminochlorothioformates in the Synthesis of Novel 2,3,4,9-Tetrahydroisothiazolo[5,4-b][1,8]Naphthyridine-3,4-Diones and 2,3,4,9-Tetrahydroisothiazolo [5,4-b]Quinoline-3,4-Dione Derivatives”, J. Heterocyclic Chem., 27: 1191-1195 (1990).
Ming, Y., Horlemann, N., Wamhoff, H., “Heterocondensed Pyridines by Cycloaddition-Extrusion Sequence of Bi- and Tricyclic 1,3-Oxazinones With N,N-Diethyl-1-Propynylamine”, Chemische Berichte, 120: 1427-1431 (1987).
Friary, R., Seidl, V., Schwerdt, J., Cohen, M., Hou, D., Nafissi, M., “Intramolecular Transaminations of Enaminones: A Synthesis of Fused, Polycyclic, N-Aryl Pyridones”, Tetrahedron, 49: 7169-7178 (1993).
Osborne, A., Goolamali, Z., “1H and13C NMR Spectra; Studies of Some 4H-3, 1-Benzoxazin-4-Ones and Their 2-Acylaminobenzoic Acid Precursors”, Spectrochimica Acta Part A, 56: 1079-1100 (2000).
Patent Abstracts of Japan, Patent No.:JP 09221424, Date: Aug. 26, 1997, “Antitumor Agent”, Kyoji, T., Katsumi, C., Shigeki, K., Katsuhisa, N., Kouichirou, S., Yasutomo, C., Masanori, T., Tomio, O.
Bullock William H.
Chen Libing
Wang Yamin
Bayer Pharmaceuticals Corporation
Dentz Bernard
Pellegrino Susan M.
LandOfFree
1,6-naphthyridine derivatives and their use to treat... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,6-naphthyridine derivatives and their use to treat..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,6-naphthyridine derivatives and their use to treat... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3521971